A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers
- Sponsor
- Janssen-Cilag International NV
- Study ID
- NCT01877889
- Phase
- PHASE1
- Status
- Completed
Conditions
- Healthy
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 55 Years
- Healthy Volunteers
- Accepted
Interventions
- Canagliflozin — DRUGOne 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 \[treatment period 2\] or Sequence 2 \[treatment period 1\]).
- Dapagliflozin — DRUGOne 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 \[treatment period 1\] or Sequence 2 \[treatment period 2\]).
Study Details
The purpose of this study is to compare the pharmacodynamics (ie, how the drug affects the body) of canagliflozin with the pharmacodynamics of dapagliflozin.
Key Dates
- Start date
- Jul 31, 2013
- Status verified
- Mar 2014
- Primary completion
- Mar 31, 2014
- Completion
- Mar 31, 2014
Study Design
- Enrollment
- 60 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: Part 1: CanaEach volunteer will receive 300 mg of canagliflozin once daily for 4 days.
- Experimental: Part 2: Sequence 1 (Dapa/Cana)Each volunteer will receive 10 mg of dapagliflozin once daily for 4 days (treatment period 1) followed by 300 mg of canagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period (with no medication).
- Experimental: Part 2: Sequence 2 (Cana/Dapa)Each volunteer will receive 300 mg of canagliflozin once daily for 4 days (treatment period 1) followed by 10 mg of dapagliflozin once daily for 4 days (treatment period 2). Each treatment period will be separated by a 12- to 14-day washout period.
Primary Outcome Measure
Between treatment difference in 24-hour mean renal threshold for glucose for canagliflozin (300 mg once daily for 4 days) compared to dapagliflozin (10 mg once daily for 4 days) [ Time Frame: Day 4 ]
Related Studies
- Study of New Magnetic Resonance Imaging Methods of the BrainRecruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland
- Mapping Auricular Vagus Nerve CircuitryEARLY_PHASE1 · Recruiting · Massachusetts General Hospital · Boston, Massachusetts
- Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group TestingRecruiting · Cedars-Sinai Medical Center · Los Angeles, California
- Evaluation and Optimization of Ultrasound and/or MRI Hardware and SoftwareRecruiting · State University of New York - Upstate Medical University · Syracuse, New York